Currently Viewing:
Currently Reading
Precursor to Blood Cancer Puts Patients at Risk Indefinitely, Study Finds
January 20, 2018 – Laura Joszt
Study Finds Prior Authorization Mandates for PCSK9 Drugs Raise Questions of Access
January 19, 2018 – Mary Caffrey
Long-Term Oral Contraceptive Use Associated With Reduced Risk of Ovarian, Endometrial Cancer
January 19, 2018 – Jaime Rosenberg
This Week in Managed Care: January 19, 2018
January 19, 2018
Wearable Biosensors Have No Significant Impact on Clinical Outcomes
January 19, 2018 – Kaitlynn Ely
Proposed Drug to Treat Oculopharyngeal Muscular Dystrophy Gains Orphan Drug Designation
January 19, 2018 – Kelly Davio
What We're Reading: House Passes CHIP Funding; Cancer Blood Test; Drug Policy Office Budget
January 19, 2018 – AJMC Staff
AJMC® in the Press, January 19, 2018
January 19, 2018 – AJMC Staff
Risk-Targeted Lung Cancer Screening Shows Modest Benefits
January 19, 2018 – Samantha DiGrande

Active Surveillance Economical Over Immediate Treatment for Low-Risk Prostate Cancer

Researchers in Canada have developed a model to simulate the cost of active surveillance versus immediate treatment among low-risk prostate cancer patients.

Active surveillance for low-risk prostate cancer in Canada could save nearly $100 million annually without worsening quality-adjusted life expectancy (QALE), according to results of a simulation comparing active surveillance with immediate treatment.

Many prostate cancers, especially those in the low-risk category, are indolent and may not require immediate treatment. At least one study has showed that QALE is greater for active surveillance than for brachytherapy, intensity-modulated radiotherapy, or radical prostatectomy.

Still, despite published guideline recommendations, as many as 90% of men with prostate cancer receive immediate treatment. Such overtreatment can be a tremendous financial burden to healthcare systems.

To see how costly it might be, Dr. Alice Dragomir and colleagues from McGill University in Montreal developed a Markov model with Monte Carlo microsimulations to estimate the direct cost associated with active surveillance and immediate treatment for low-risk prostate in Canada.

Then, they compared Canadian and US cost estimates, and published their findings online April 24th in CMAJ Open.

Source: Medscape

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!